$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Introduction to the formal purchasing channels of Erdafitinib (Bocco) and comparison of drug purchasing methods at home and abroad
2026-02-01 22:25:32
Check Details
The relationship between Erlotinib and Lorit and the differences between different packaging versions
2026-02-01 22:25:32
Check Details
The main contents, usage, dosage and precautions of the official instructions of Tofacitinib (Shangjie)
2026-02-01 22:25:32
Check Details
A comprehensive introduction to the possible side effects and risks of cycloserine during long-term use
2026-02-01 22:25:32
Check Details
How many times a day should linezolid (Siwo) tablets 600 mg be taken to meet the standard dosage requirements?
2026-02-01 22:25:32
Check Details
Whether ribociclib (Calilon) is strictly a targeted drug and a detailed analysis of its CDK4/6 inhibition mechanism
2026-02-01 22:25:32
Check Details
Is cemiplimab available in China and the status of its listing and channel availability in China
2026-02-01 22:25:32
Check Details
The latest progress of Daprodustat as well as global marketing trends and clinical research directions
2026-02-01 22:25:32
Check Details
Durvalumab (durvalumab) standard usage and dosage and instructions for individualized regimens for different patients
2026-02-01 22:25:32
Check Details
How long does the usual injection course of Zolbetuximab take and the factors that affect the length of the course?
2026-02-01 22:25:32
Check Details
How much does a box of EIKANCE 0.01% Atropine Sulfate Eye Drops cost in the market and the main factors affecting the price?
2026-02-01 22:25:32
Check Details
Analysis of common adverse reactions of Teritusumab/Telivac
2026-02-01 22:25:32
Check Details
1
2
...
2430
2431
2432
2433
2434
2435
2436
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
3
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
4
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
5
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
6
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
7
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
8
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
9
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
10
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
11
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
12
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy